Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers-Reference-Cited by-同舟云学术

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

Published:2022-01 Issue:1 Volume:8 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Nørgaard Caroline Holm¹²,Friedrich Sarah³,Hansen Charlotte Thim⁴,Gerds Thomas⁵,Ballard Clive⁶,Møller Daniel Vega⁴,Knudsen Lotte Bjerre⁷,Kvist Kajsa⁴,Zinman Bernard⁸,Holm Ellen⁹,Torp‐Pedersen Christian¹¹⁰^ORCID,Mørch Lina Steinrud⁴

Affiliation:

1. Department of Cardiology and Clinical Research Nordsjællands University Hospital Hillerød Denmark

2. Department of Medicine University of California Irvine Irvine California USA

3. Department of Medical Statistics University Medical Center Göttingen Göttingen Germany

4. Novo Nordisk Søborg Denmark

5. Section of Biostatistics Copenhagen University Østerbro Denmark

6. St Luke's Campus University of Exeter College of Medicine and Health Exeter UK

7. Novo Nordisk Måløv Denmark

8. Lunenfeld–Tanenbaum Research Institute Mount Sinai Hospital University of Toronto Toronto Ontario Canada

9. Department of Medicine Nykøbing Falster Hospital Hospitalsvej Nykøbing Falster Denmark

10. Department of Cardiology Aalborg University Hospital Aalborg Denmark

Funder

Novo Nordisk

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12268

Reference35 articles.

1. World Alzheimer Report 2016. Improving healthcare for people living with dementia;Prince M;Alzheimers Dis Int,2016

2. International Diabetes Federation. IDF Diabetes Atlas Ninth Edition 2019.2019;

3. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges;Life Sciences;2024-10

2. Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks;Diabetes, Obesity and Metabolism;2024-09-09

3. Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia;Annals of Internal Medicine;2024-08-27

4. Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline;Biomedicines;2024-08-03

5. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission;The Lancet;2024-08